ifetroban

2023年5月23日—Ifetrobanisapotentandselectivethromboxane-prostanoidreceptor(TPr)antagonist.IfetrobanexhibitshighaffinityforTPronmanycell ...,2023年5月24日—CumberlandPharmaceuticalshasannouncedplanstolaunchthePhaseIIFIGHTINGFIBROSIStrialoforalifetrobanforIPF.,Ifetrobanisapotentandselectivethromboxanereceptorantagonist.Ithasbeenstudiedinanimalmodelsforthetreatmentofcancermetastasis, ...,2-[[(1S,2...

參考資訊如下
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA ...

2023年5月23日 — Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist. Ifetroban exhibits high affinity for TPr on many cell ...

Cumberland to launch Phase II trial of ifetroban for IPF

2023年5月24日 — Cumberland Pharmaceuticals has announced plans to launch the Phase II FIGHTING FIBROSIS trial of oral ifetroban for IPF.

Ifetroban

Ifetroban is a potent and selective thromboxane receptor antagonist. It has been studied in animal models for the treatment of cancer metastasis, ...

Ifetroban = 98 HPLC 156715-37

2-[[(1S,2R,3S,4R)-3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid sodium salt, BMS 180291-02, ...

Ifetroban in Treating Patients with Malignant Solid Tumors ...

This phase II trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after ...

Ifetroban sodium (Synonyms: BMS

Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for ...

Ifetroban sodium

由 L Rosenfeld 著作 · 2001 · 被引用 53 次 — Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115. doi: 10.1111/j.1527-3466.2001.tb00058.x.

Ifetroban | C25H32N2O5

Ifetroban is an orally bioavailable thromboxane (TxA2) and prostaglandin H2 (PGH2) (TP) receptor antagonist, with anti-thrombotic, anti-hypertensive, ...